The Incyte Ingenuity Awards in GVHD

Supporting the graft-versus-host disease (GVHD) community

The 2024 Incyte Ingenuity Awards in GVHD are now open for applications! Learn about eligibility and how to apply.

Offering Two Awards for Outstanding Initiatives

One for $35,000 and another for $100,000

The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.

GVHD is a life-threatening condition that occurs when donor immune cells attack the recipient's organs and tissues after an allogeneic stem cell transplant. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems, including the skin, the digestive tract, and the liver. Both acute and chronic GVHD are associated with significant morbidity and mortality.

Incyte is deeply dedicated to improving the lives of patients with serious diseases, including GVHD. As a part of this commitment, the company is excited to reopen the Incyte Ingenuity Awards application period to continue to foster collaboration amongst key stakeholders to address the specific needs of the GVHD community.

Submit your application by June 24, 2024 for the chance to be awarded up to $100,000 to help people living with GVHD.

What To Consider Before Applying?

Meredith Cowden, Director of Patient Advocacy, The Meredith A. Cowden Foundation, provides an overview of the application process and outlines three rules to consider before submitting an application.


Eligibility Information

The following groups and individuals are eligible to apply for the Incyte Ingenuity Awards in GVHD:

Image of hands holding heart

Non-profit 501(c)(3), patient, policy, and caregiver organizations

Image of caduceus

Healthcare providers and mid-level/junior faculty of healthcare organizations*

Image of two people

Individuals or other companies collaborating with these organizations and institutions**

Programs must be independent of any ongoing activities, with the exception of considerably expanding an existing program. Additionally, programs cannot include indirect costs with the proposed budget. To be eligible, you and your organization must be US based (including Washington DC and Puerto Rico).

*Applications must be submitted in the name of an institution, not on behalf of an individual.

**Individuals or other companies interested in applying must partner with either a non-profit organization or a healthcare facility (i.e., hospitals, academic research centers, etc.) to be eligible.

Applications will be disqualified if:

  • Focus is on a particular therapeutic agent, translational research, or clinical research that is interventional in nature
  • Program is based on an existing initiative, with no evidence of ingenuity
  • Organization is improperly identified as a 501(c)(3) organization
  • Application is submitted by a healthcare professional as an individual (individuals will need to partner with a not-for-profit or other organization to be considered)
  • Defined scope does not serve or plan to address a specific need of the GVHD community
  • Request in funding exceeds 25 percent of an organization's overall annual budget and/or includes indirect costs
  • Application is submitted by an employee of Incyte, Real Chemistry, and/or other vendors, or members of the immediate family of any such persons
  • Program is duplicated, with multiple copies of an application submitted by the same organization
  • Program exceeds the maximum application limit per organization (more than five)
  • Program includes monetary support, gifts, or other items of monetary value to patients, either directly or indirectly
  • Applicant and/or organization are not based in the United States

Incyte reserves the right to modify the eligibility requirements at any time.

Have additional questions? Check out our FAQ page.

Peg Squier, Group Vice President, U.S. Medical Affairs, Incyte, provides an overview of the program, outlines eligibility requirements, and the necessary steps in submitting an application.

Meet the Judges

Meet the Judges

Meet our 2024 Incyte Ingenuity Awards in GVHD judging panel!

Image of Alice Houk

Alice Houk

Alice Houk is the Senior Director of Patient and Professional Services of the Aplastic Anemia & MDS International Foundation (AAMDS). The mission of AAMDS is to support patients and families living with aplastic anemia, myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. At AAMDS, Houk plans and develops all medical education programs, including symposia at national medical conferences, the biennial AAMDS scientific symposium, and web-based programs. She also oversees AAMDS patient education programs and services. Houk serves as liaison to the Foundation’s medical advisory board and with other professional and patient organizations, and she manages the Foundation’s research grant program. She holds a master's degree in Health Policy from the University of Maryland and a Nonprofit Executive Management Certificate from Georgetown University. Houk and AAMDS were also the recipients of the 2021 Incyte ingenuity Awards in GVHD. Learn more about her award-winning project.

Image of Barbara Abernathy, PhD, LMHC

Barbara Abernathy, PhD, LMHC

Dr Barbara Abernathy is the President and CEO of the Pediatric Oncology Support Team, Inc. (POST), a nonprofit helping children and their families cope with the devastating effects of cancer. She has 35 years’ experience in nonprofits, 25 of those years at POST. Being a cancer survivor herself, she brings a personal touch to the children and families battling childhood cancer. She is also a vigorous advocate for those fighting blood cancer, facing a bone marrow transplant, or dealing with GVHD. She is adjunct faculty at the University of Miami Miller School of Medicine and Florida Atlantic University and has authored scholarly peer-reviewed articles. Dr Abernathy has been an invited speaker at many national and international professional conferences, including being the keynote speaker for the BMT Infonet conference in 2019.

Image of Doris Ponce, MD

Doris Ponce, MD

Dr Doris Ponce is an Associate Professor of Medicine as well as the GVHD Program Director at Memorial Sloan Kettering Cancer Center. Her research experience focuses on allogeneic stem cell transplantation (allo-HCT) with an emphasis on GVHD. She conducts research for the prevention and treatment of acute and chronic GVHD, including investigator-initiated translational studies. Dr Ponce established a multidisciplinary GVHD clinic at her institution that currently serves a wide catchment area. Dr Ponce has been the recipient of several funding awards and her work has been featured in the journal Blood and presented in national and international meetings.

Image of Dr Pooja Khandelwa

Pooja Khandelwal, MD

Dr Pooja Khandelwal is a member of the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center and serves as Associate Professor in the UC Department of Pediatrics. She graduated from Kasturba Medical College in Manipal, India, completed her residency at the University of Arizona College of Medicine, and completed her fellowship at Cincinnati Children's Hospital Medical Center. Dr Khandelwal is a pediatric hematologist-oncologist specializing in bone marrow transplantation for hemoglobinopathies, malignancies and metabolic disorders. She also runs a multidisciplinary clinic focused on taking care of children with chronic GVHD. Her research interests focus on restoring and maintaining intestinal homeostasis in patients during the peri-transplant period. Her goal is to reduce the incidence of GVHD by using a variety of approaches, such as administration of specific nutritional compounds and modification of the intestinal microbiome. Dr Khandelwal and her organization were also recipients of the 2022 Incyte Ingenuity Awards in GVHD.

Image of Susan Stewart

Susan Stewart

Susan Stewart is the Founder and Executive Director of the Blood and Marrow Transplant Information Network (BMT InfoNet). BMT InfoNet is a not-for-profit organization that provides information and support services to bone marrow, peripheral blood stem cell and cord blood transplant (hematopoietic cell transplant) recipients before, during and after treatment. At BMT InfoNet, Stewart oversees all operations, and as a transplant survivor herself, she brings great insight and perspective to her work. She is widely considered a vital resource to the entire transplant community. Stewart also authored Bone Marrow and Blood Stem Cell Transplants: A Guide for Patients; Autologous Stem Cell Transplants: A Handbook for Patients; Graft-versus-Host Disease: What to Know, What to Do; and CAR T-Cell Therapy: What to Expect Before, During and After – all of which are used extensively by transplant centers throughout the U.S. and Canada to educate patients. Stewart holds a degree in Sociology/Urban Affairs from Northwestern University.

alert icon

Incyte will not provide any advice or input during the judging process, and all decisions made by the judging panel are made independently and are final. These judges will receive compensation for their services from Incyte, based on fair market value.

Judging Criteria

Judging Criteria

Our independent judging panel will consider the following criteria when evaluating each award application:

Checkmark iconDoes the applicant meet the eligibility requirements?

Handshake iconDid the applicant collaborate with any other organizations to optimize the success of the initiative?

Documents iconDoes the application contain all of the necessary details and supporting documents?

Puzzle piece iconDoes the proposal exhibit a thoughtful, creative and innovative approach to address a specific need within the GVHD community?

Stopwatch iconCan the proposal be completed within the one-year time frame?

Target iconDoes the proposal demonstrate a clear purpose and rationale?

Dollar sign iconDoes the proposal include a realistic and appropriate budget?

Upward pointing arrow iconDoes the proposal have clear and measurable outcomes? Does it follow the SMART (specific, measurable, achievable, realistic, timely) methodology for setting goals?

Incyte reserves the right to change the judging criteria at any time.

Program Rules

Program Rules

The application process will occur in two rounds:

Icon of the number 1Round one

Complete a letter of intent that introduces your proposal that includes the following:

  • Confirmation of eligibility criteria
  • Contact and organization information
  • Indicate which award the project is applying for
  • Project proposal, including project name, objectives, simplified budget and summary of how it addresses a specific need for the GVHD community
  • Identification of any collaboration and connection to the GVHD community

Icon of the number 2Round two

Applicants who progress to round two will be asked to complete an additional form, further detailing their proposal, as well as specific questions from the judging panel via email that address:

  • Detailed budget breakdown and timeline of milestones to execute initiative within one year of selection
  • Measurable elements and anticipated outcomes that will define success and demonstrate impact
  • Identification of any organizational challenges in execution
  • Specific questions, unique to each application, based on information the judging panel members would like the applicant to clarify and/or expand upon

Have additional questions? Check out our FAQ page.